Vibeleaderboard
Index / tool
Visit github.com
Category
Developer Tools
Rank
No. 3790Tools index

Previous survey · No. 3593 ·

Type
TOOL
Use case
Security & Identity
Interfaces
MCP
GitHub
1 stars
Latest release
v0.1.0beta2
Date

About

Venya is a privileged access management system that lets AI agents perform privileged operations through the Model Context Protocol without the agent ever handling the underlying secrets directly. It combines FIDO2 authentication with remote executor sandboxes to broker and constrain what an LLM-driven operation can actually do.

At a glance

Venya separates an agent’s command request from the infrastructure credential used to execute it. It is worth evaluating if agents need to perform narrowly defined operations and you can operate a separate executor and approval process.

Good fit

Infrastructure teams that can manage credential scopes, review the executor boundary and inspect audit events.

Consider something else when

Keep manual operations if you cannot isolate the executor or define what an agent is allowed to request.

Start here

Read the authorization and execution path. In a test environment, verify one permitted action and one denied action with a synthetic credential and inspect the resulting audit records.

Cost and requirements

The repository uses a Business Source License with an additional-use grant. Review those terms and the documented self-hosting requirements before deployment.

Limits to know

Credential injection limits one exposure path. Verify which commands the credential can authorize, what outputs reveal and what a compromised executor could access.

Why it made the leaderboard

Venya lets LLM agents perform privileged operations through remote executor sandboxes and MCP without ever exposing the underlying secrets to the model, using FIDO2 authentication to gate access.

Tags

pamai-agentsfido2mcpsecrets-management

Tech Stack

Python

Comments (0)

No comments yet

Editorially curated, with community endorsements as a secondary signal. Corrections welcome.